| Name | Value |
|---|---|
| Revenues | 6,981.0K |
| Cost of Revenue | 2,521.0K |
| Gross Profit | 4,460.0K |
| Operating Expense | 5,918.0K |
| Operating I/L | -1,458.0K |
| Other Income/Expense | -442.0K |
| Interest Income | 0.0K |
| Pretax | -1,900.0K |
| Income Tax Expense | 261.0K |
| Net Income/Loss | -2,161.0K |
ImmunoPrecise Antibodies Ltd. is a leading provider of antibody production and related services globally. The company offers a diverse range of antibodies, enzymes, proteins, and hybridoma products for research purposes. Its contract research organization services encompass custom antigen modeling, B cell sorting, antibody engineering, and cell line generation. ImmunoPrecise Antibodies has research collaboration agreements with industry leaders for antibody discovery and high-concentration formulation of COVID-19 antibody cocktails. The company generates revenue through the sale of its antibody products, contract research services, and collaborative research agreements.